Post Test and Evaluation Please note that to receive credit you must achieve a score of at least 70%. Certificate of Credit will be emailed within 4 weeks of successful completion of the activity. Post-Activity Test Question Title 1. Which of the following best describes stress incontinence? Overactive bladder without leakage episodes. Leakage episodes associated with exertion (i.e., coughing, sneezing, etc.). Leakage episodes due to strong urgency. Leakage episodes associated with a transient condition (e.g., delirium, UTI, etc.). Question Title 2. A factor that contributes to urge incontinence is: UTI Detrusor overactivity Pelvic floor weakness Urethral hypermobility Question Title 3. A 50-year-old woman presents with a main complaint of a frequent urge to urinate (every 1–2 hours) and nocturia (1–2 times per night). She does not report incontinence episodes. The most appropriate initial diagnostic step is: Urinalysis with culture Pelvic ultrasound Urodynamics Cystoscopy Question Title 4. Which of the following lifestyle changes can improve OAB symptoms? Take a daily calcium supplement Reduce weight if overweight Cease all alcohol consumption Daily use of feverfew Question Title 5. You see a 52-year-old woman who complains of urinary frequency about once every hour and nocturia (1–2 times per night). She describes a strong urinary urgency and often experiences incontinence episodes. Her medical history is unremarkable, lab results are within normal limits, and urinalysis is normal. According to AUA, an appropriate first-line management option for this patient is: Behavioral therapy plus an antimuscarinic or beta3-agonist Antimuscarinic therapy alone Beta3-agonist therapy alone Antimuscarinic plus beta3-agonist All of the above Question Title 6. When considering prescribing antimuscarinic therapy, which of the following is most accurate? Some antimuscarinics have been shown to provide superior efficacy over other antimuscarinics. Maximum effect is usually observed within 1 week of antimuscarinic use. Dosing should start at the highest dose possible. Extended-release formulations are preferred over immediate-release formulations. Question Title 7. For an OAB patient who fails to get an adequate response with behavioral therapy, an appropriate second-line treatment can include any of the following except: Immediate-release antimuscarinic therapy Extended-release antimuscarinic therapy Beta3-agonist Botulinum toxin injection Question Title 8. Which of the following adverse effects is most common with antimuscarinic agent use? Diarrhea Rash Dry mouth Postural hypotension Question Title 9. You see a 56-year-old woman with OAB who failed to respond adequately to behavioral therapy and initiated treatment with oxybutynin 3 weeks ago. She returns for a follow-up visit and states that she stopped using her medication 1 week ago because of constipation. She did notice some improvement in OAB symptoms during the 2 weeks she was taking the medication. Appropriate options to manage this patient include all of the following except: Attempt to manage the adverse effects of her current medication Switch to another antimuscarinic agent Switch to a beta3-agonist Add a beta3-agonist to the prior regimen Question Title 10. For a patient with OAB who has failed monotherapy with different antimuscarinic agents due to inadequate response or adverse effects, an appropriate option would be all of the following except: Convince the patient to live with the condition Switch to a beta3-agonist Consider combination therapy Referral to a urologist Next
